Literature DB >> 100893

Persistent hyperplastic primary vitreous. A clinicopathologic study of 62 cases and review of the literature.

R Haddad, R L Font, F Reeser.   

Abstract

This is a clinicopathologic study of 62 cases of persistent hyperplastic primary vitreous (PHPV). The cases were divided into two main groups. Group 1 consisted of 55 unilateral cases not associated with any systemic abnormalities, including 36 eyes (58%) which were considered "pure cases" (Group 1A) and 19 (31%) which disclosed other ocular abnormalities in addition to PHPV (Group 1B). Group 2 consisted of 7 (11%) bilateral cases of PHPV accompanied by other ocular and systemic malformations. The most common presenting clinical signs are leukocoria, microphthalmia and cataract. The main histopathologic features of this condition are outlined, including those responsible for the disastrous results to the eye (retinal detachment, glaucoma, phthisis bulbi). Several clinical entities, usually mistaken for or associated with PHPV, such as retinoblastoma, congenital cataract, retinal dysplasia, trisomy 13 syndrome, and falciform retinal folds are discussed briefly.

Entities:  

Mesh:

Year:  1978        PMID: 100893     DOI: 10.1016/0039-6257(78)90091-7

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  43 in total

1.  Histopathological examination of two cases of anterior staphyloma associated with Peters' anomaly and persistent hyperplastic primary vitreous.

Authors:  A Matsubara; H Ozeki; N Matsunaga; M Nozaki; M Ashikari; S Shirai; Y Ogura
Journal:  Br J Ophthalmol       Date:  2001-12       Impact factor: 4.638

2.  Ultrastructural pathology of anterior persistent hyperplastic primary vitreous.

Authors:  M Spitznas; F Koch; S Pohl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

3.  ATOH7 mutations cause autosomal recessive persistent hyperplasia of the primary vitreous.

Authors:  Lev Prasov; Tehmina Masud; Shagufta Khaliq; S Qasim Mehdi; Aiysha Abid; Edward R Oliver; Eduardo D Silva; Amy Lewanda; Michael C Brodsky; Mark Borchert; Daniel Kelberman; Jane C Sowden; Mehul T Dattani; Tom Glaser
Journal:  Hum Mol Genet       Date:  2012-05-29       Impact factor: 6.150

4.  Advanced bilateral persistent fetal vasculature associated with a novel mutation in the Norrie gene.

Authors:  S Dhingra; D J Shears; V Blake; H Stewart; C K Patel
Journal:  Br J Ophthalmol       Date:  2006-10       Impact factor: 4.638

5.  Outcomes in persistent hyperplastic primary vitreous.

Authors:  A Hunt; N Rowe; A Lam; F Martin
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

6.  Ultrastructure of persistent hyperplastic primary vitreous (PHPV)

Authors:  H Witschel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

7.  Normal Developmental Globe Morphology on Fetal MR Imaging.

Authors:  M T Whitehead; G Vezina
Journal:  AJNR Am J Neuroradiol       Date:  2016-04-21       Impact factor: 3.825

8.  Formation of persistent hyperplastic primary vitreous in ephrin-A5-/- mice.

Authors:  Alexander I Son; Michal Sheleg; Margaret A Cooper; Yuhai Sun; Norman J Kleiman; Renping Zhou
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-19       Impact factor: 4.799

9.  p19Arf represses platelet-derived growth factor receptor β by transcriptional and posttranscriptional mechanisms.

Authors:  Ryan C Widau; Yanbin Zheng; Caroline Y Sung; Anna Zelivianskaia; Lauren E Roach; Karen M Bachmeyer; Tatiana Abramova; Aurelie Desgardin; Andrew Rosner; John M Cunningham; Stephen X Skapek
Journal:  Mol Cell Biol       Date:  2012-08-20       Impact factor: 4.272

10.  Pathogenesis of persistent hyperplastic primary vitreous in mice lacking the arf tumor suppressor gene.

Authors:  Amy C Martin; J Derek Thornton; Jiewiu Liu; XiaoFei Wang; Jian Zuo; Monica M Jablonski; Edward Chaum; Frederique Zindy; Stephen X Skapek
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-10       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.